This study was designed to investigate the in vivo growth inhibitory effects of celecoxib, a cyclo-oxygenase-2 inhibitor, and fluvastatin, a 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor, on the hepatocellular carcinoma (HCC) cell line, BEL-7402. Athymic nude mice implanted with BEL-7402 cells were given celecoxib and fluvastatin, either alone or in combination, and the effect of treatment on tumour growth was evaluated after 6 weeks. The combination of celecoxib and fluvastatin enhanced inhibition of tumour growth, induction of apoptosis, inhibition of tumour cell proliferation, and inhibition of tumour angiogenesis compared with either treatment alone. The combination of celecoxib and fluvastatin also increased levels of the cyclin-dependent kinase inhibitor p21 Waf1/Cip1 , decreased levels of p-Akt, myeloid cell leukaemia-1 (Mcl-1) and survivin protein, but had no effect on Akt protein levels in tumours. These results suggest that celecoxib combined with fluvastatin would be more efficacious for the treatment of HCC than either treatment alone and this combination of therapy warrants further research.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common solid tumour in the world and the third leading cause of cancer-related death. 1 It is often associated with chronic liver diseases, such as liver cirrhosis and chronic viral hepatitis, is usually diagnosed at an advanced stage and with a particularly poor prognosis. 2 Partial hepatic resection is generally regarded as the treatment of choice for HCC, with reported 5-year overall survival rates of up to 50%. 3 Unfortunately, poor hepatic functional reserve, tumour burden or location preclude traditional hepatic resection in many patients. 4 Various alternative therapies, such as transarterial *J Gao and W-D Jia contributed equally to this work as joint first authors. J Gao, W-D Jia, J-S Li et al. In vivo anticancer effects of celecoxib and fluvastatin combination therapy chemoembolization (TACE), ultrasoundguided radiofrequency ablation (RFA) and orthotopic liver transplantation (OLT), 5 -7 have been investigated but there is still no satisfactory treatment for HCC. Thus, there is a clear clinical need for the development of more effective therapies.
Celecoxib is a non-steroidal antiinflammatory drug (NSAID) and a highly selective inhibitor of cyclo-oxygenase-2 (COX-2), which is a rate-limiting enzyme in the prostaglandin synthesis pathway. 8 COX-2 and its metabolite prostaglandin E 2 (PGE 2 ) play important roles in a variety of biological activities, such as increased angiogenesis, enhanced cell proliferation and resistance to apoptosis. 9 -11 High levels of COX-2 have been found in several types of cancers, including HCC, pancreatic carcinoma, lung carcinoma, prostatic carcinoma and colorectal carcinoma. 12 -16 Theoretically, potent and selective inhibition of COX-2 would inhibit tumour development. In fact, both in vitro and in vivo studies have shown that celecoxib and other COX-2 inhibitors can effectively inhibit the growth of bladder, prostate cancer and other solid tumours, including HCC; 17 -20 and the activities of these agents were significantly attributable to the induction of apoptosis and the reduction of proliferation. The longterm use of high-dose COX-2 inhibitors including celecoxib may, however, be associated with an increased incidence of cardiovascular side-effects. 21 Fluvastatin, a member of the statin family of drugs, is commonly used for the treatment of patients with hypercholesterolaemia. 22 Statins inhibit the activity of 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting step in the cholesterol biosynthesis pathway. 23 In addition to their cholesterol-lowering activities, statins are regarded as a new class of antineoplastic agent, based on the observation that the activity of HMG-CoA reductase is up-regulated in several types of human cancers. 24, 25 It has been shown that statin use is associated with improved cardiovascular health status and levels of inflammatory mediators in patients with heart failure. 26 Although fluvastatin and other statins have been shown to induce apoptosis in HCC cells, 27 the effects of fluvastatin alone or in combination with other drugs on the growth of HCC xenografts transplanted into athymic mice are not yet known.
The concept of using combinations of drugs for the treatment of cancers has been used successfully in clinical practice for many decades. Combinations of two or more anticancer agents that target the cancer in different ways have been suggested as a promising therapeutic strategy both to maximize pharmaceutical efficacy and to minimize the adverse events associated with the individual components. For example, it has been shown that the administration of a combination of celecoxib and atorvastatin produced enhanced inhibitory activities against tumour growth in both immunodeficient and adenomatous polyposis coli min/+ (APC min/+ ) mouse models. 28, 29 We hypothesized that a combination of celecoxib and fluvastatin would produce greater efficacy against human HCC BEL-7402 xenografts than either treatment alone. The effects of these agents on BEL-7402 xenograft growth in athymic nude mice were measured and, in order to investigate the potential mechanisms of action of their anticancer effects, the expression of several signalling molecules in the BEL-7402 tumour xenografts were examined using immunohistochemical staining and Western blotting. 
IN VIVO TUMOUR XENOGRAFT STUDIES
Male BALB/c athymic nude (nu + /nu + ) mice (4 -5 weeks old) were purchased from the Shanghai Laboratory Animal Centre of the Chinese Academy of Sciences (Shanghai, China). All animal studies were approved by the Institutional Animal Care and Use Committees of Anhui Province Medical Animal Centre and Anhui Medical University (Hefei, China).
The BEL-7402 cells were removed from the culture dishes with trypsin and then collected, washed and resuspended in DMEM. To establish BEL-7402 tumour xenografts, mice were injected subcutaneously into the left armpit with 5 × 10 6 BEL-7402 cells mixed with 100 µl DMEM. The mice were randomized into four groups (n = 8 in each group) as follows: an untreated control group, a celecoxib treatment group, a fluvastatin treatment group, and a combined celecoxib and fluvastatin treatment group. Mice in the three treatment groups were administered, by oral gavage, celecoxib 25 mg/kg per day, fluvastatin 15 mg/kg per day, or celecoxib 25 mg/kg per day plus fluvastatin 15 mg/kg per day for 6 weeks. The untreated control mice received an equal volume of carrier solution by oral gavage. The dose of celecoxib was selected based on previous preclinical studies and was expected to be non-toxic. 19 Fluvastatin at a dose of 15 mg/kg per day in mice is considered equivalent to a human dose of 80 mg/day (based on body surface area equivalency). 30 Based on our preliminary experiments and these previous reports, 19, 30 the doses of the two drugs were specially chosen so that their independent effects on tumour growth inhibition would be modest. The size of the tumour was measured twice weekly by vernier calliper for the duration of the study and the tumour volume was calculated from the three diameters (length, width and height) using the previously reported formula: 31 volume (mm 3 ) = length × width × height × π/6. The mice were sacrificed to harvest the tumour tissue 6 weeks after tumour cell implantation. One part of each tumour was fixed in formalin for immunohistochemical staining and the other part was immediately frozen in liquid nitrogen and stored at -80°C.
IMMUNOHISTOCHEMISTRY AND MEASUREMENT OF APOPTOSIS
To investigate whether antitumour effects were caused by inhibition of cell proliferation, the effect of treatment on tumour cell proliferation was evaluated by immunohistochemical analysis of Ki-67 expression.
In addition, tumour angiogenesis is considered a vital prognostic biomarker correlating with the growth and development of HCC. So, in order to assess J Gao, W-D Jia, J-S Li et al. In vivo anticancer effects of celecoxib and fluvastatin combination therapy the effect of treatment on tumour angiogenesis, intratumour microvessel density (MVD) was examined by immunohistochemical staining for the cell surface marker, CD34. A reduction in the CD34 level would indicate that the treatments might modulate the level of vascular endothelial growth factor (VEGF) protein in tumour xenografts, which could be a potential target for antiangiogenic therapy. To evaluate the effect of the treatments on VEGF protein levels, immunohistochemical staining for VEGF protein was, therefore, also carried out.
Formalin-fixed, paraffin-embedded tumour sections (5 µm) were used for the immunohistochemical analyses. They were rehydrated, deparaffinized and blocked for endogenous peroxidase activity. The sections were then incubated overnight at 4°C with specific primary antibodies, including antihuman Ki-67 monoclonal antibody (1:100 dilution; Zhongshan Golden Bridge Biotechnology Co. Ltd, Beijing, China), antihuman VEGF monoclonal antibody (1:50 dilution; Zhongshan Golden Bridge Biotechnology Co. Ltd.) and rat antimouse CD34 monoclonal antibody (1:50 dilution; Beijing Biosynthesis Biotechnology Co. Ltd, Beijing, China). After washing three times with 10 mM phosphate-buffered saline (PBS), pH 7.4, the slides were incubated with the appropriate biotinylated secondary antibody (1:100-1:200 dilutions; Zhongshan Golden Bridge Biotechnology Co. Ltd) for 30 min at 37°C. The sections were then washed in 10 mM PBS and incubated for 30 min with streptavidin-peroxidase complex (Zhongshan Golden Bridge Biotechnology Co. Ltd) according to the manufacturer's instructions. The colour reaction was developed with 3,3′diaminobenzidine and the slides were counterstained with haematoxylin and eosin.
Apoptosis was measured using a terminal deoxynucleotidyl transferase-mediated nickend labelling (TUNEL) assay undertaken with an in situ cell death detection kit (Roche, Basel, Switzerland) as described by the manufacturer.
The numbers of Ki-67-positive cells and TUNEL-positive cells were quantified at × 400 magnification and at least 1000 cells were counted for each section. The apoptotic and proliferation indices were determined by counting the number of positive cells per 1000 tumour cells in five fields (× 400 magnification) for each section. The MVD was evaluated as described by Weidner et al. 32 The intensity of VEGF-positive staining was semi-quantitatively scored as: 0, absent; 1, weak; 2, moderate; 3, strong; and 4, very strong.
WESTERN BLOT ANALYSIS
Western blot analysis was used to examine several molecules that are relevant to tumour growth. Total tumour lysates were prepared from frozen tissue as described previously. 33 Tumour cell lysate proteins were fractionated using 4 -20% sodium dodecylsulphate-polyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride membranes. After blocking in 5% (w/v) non-fat dry milk in Tris-buffered saline (TBS; 20 mM Tris pH 7.5, 150 mM NaCl) with 0.1% (v/v) Tween ® 20 (TBST) for 1 h at room temperature, the membranes were incubated overnight at 4°C with specific primary antibodies for phospho-Akt . Staining with an anti-βactin antibody (1:500 dilution; Santa Cruz Biotechnology) was used as the constant internal total protein control. The membranes were then washed with TBST to remove the primary antibodies and incubated at room temperature for 1 h with horse radish peroxidase-conjugated antimouse, antirabbit, or antigoat secondary antibodies (1:100 dilution; Zhongshan Golden Bridge Biotechnology Co. Ltd) before being washed again in TBST. Finally, proteins were visualized by enhanced chemiluminescence detection (SuperSignal ® West Femto Maximum Sensitivity Substrate; Pierce Protein Research Products, Thermo Scientific, Rockford, IL, USA) and exposed to X-ray film. These experiments were repeated a minimum of three times.
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® , with data expressed as mean ± SD. The tumour volume of each treatment group was compared using analysis of variance. Histological data were analysed using the Student's t-test. A P-value < 0.05 was considered to be statistically significant.
Results

TUMOUR GROWTH
Mean tumour volume versus time profiles after the administration of vehicle control, celecoxib, fluvastatin and the combination of celecoxib with fluvastatin in mice with BEL-7402 xenografts are shown in Fig. 1A and the visual appearance of the mice at the end of the 6 weeks of treatment is shown in Fig. 1B . The mice that received the combined treatment of celecoxib plus fluvastatin had the largest reduction in tumour growth over the 6 weeks of treatment. At 42 days (6 weeks) post-tumour cell implantation, the mean tumour volumes in mice treated with vehicle control, celecoxib, fluvastatin and combined therapy were 2340.2 ± 563.7, 1545.5 ± 244.1, 1756.5 ± 363.5 and 650.3 ± 286.1 mm 3 , respectively. These results demonstrated a 72% reduction in tumour volume with combined therapy, a 34% reduction with celecoxib and a 25% reduction with fluvastatin compared with the vehicle-treated control mice. The combined treatment of celecoxib and fluvastatin significantly inhibited tumour growth compared with the vehicle control (P < 0.001), celecoxib alone (P < 0.001), and fluvastatin alone (P < 0.001). No weight loss or behavioural changes were observed in the mice and no histopathological changes were observed in the major organs (data not shown).
TUMOUR PROLIFERATION AND APOPTOSIS
Examination of the effects of the treatments on tumour cell proliferation by immunohistochemical staining for Ki-67 expression is shown in Figs 2A and 2B . The proportion of Ki-67-positive cells in the control group was 78.7 ± 10.6%, while the percentage with celecoxib or fluvastatin treatment alone was 67.4 ± 12.3% and 69.2 ± 14.2%, respectively (P < 0.05 versus control). Combination therapy showed a significantly greater inhibition of tumour cell proliferation in comparison with the control and single-therapy groups (proliferation index 51.9 ± 15.9%; P < 0.001 versus control; P < 0.05 versus celecoxib or fluvastatin groups).
Evaluation by TUNEL analysis of whether any of the treatments would induce apoptosis showed few apoptotic cells in tumours from the control mice, whereas a large number of apoptotic cells were detected 
TUMOUR MVD AND VEGF PROTEIN LEVEL
In terms of the effect of treatment on tumour angiogenesis, representative intratumour MVD examined by evaluating the extent of Significantly more CD34-positive cells were seen in tumours from the untreated control group compared with tumours from the drug treatment groups (P < 0.001; Fig. 3B ). Tumours in the control group of mice showed 27.88 ± 4.38% CD34-positive cells compared with 18.08 ± 2.12% (35% decrease) in the celecoxib group, 21.23 ± 3.05% (24% decrease) in the fluvastatin group and 12.03 ± 2.17% (57% decrease) in the combination-treated group, respectively. The combination group showed significantly fewer CD34-positive cells than Representative VEGF immunohistochemical staining is shown in Fig. 3C . Immunohistochemical staining of tumours after 6 weeks of treatment with the celecoxib and fluvastatin treatment combination revealed a significant decrease in expression of VEGF (P < 0.001 versus all other treatment groups; Fig. 3D ).
P-AKT AND TOTAL AKT PROTEIN LEVELS
Western blot analysis showed that the combination of celecoxib and fluvastatin for 6 weeks gave a much greater reduction of p-Akt than either agent alone; celecoxib or fluvastatin alone only slightly reduced the level of p-Akt compared with the untreated control. The total level of Akt was not affected by any of the treatments (Fig. 4 ).
P21 WAF1/CIP1 , MCL-1 AND SURVIVIN PROTEIN LEVELS
Western blot analysis was used to examine several molecules that are relevant to tumour growth. Observations indicated up-regulation of the expression of p21 Waf1/Cip1 , a cyclin-dependent kinase inhibitor, in the tumours of mice that had received the celecoxib and fluvastatin combination treatment (Fig. 5 ). High levels of Mcl-1 protein were seen in HCC tumours and these were reduced by 6 weeks of the combination of celecoxib and fluvastatin, whereas celecoxib or fluvastatin alone showed smaller reductions in Mcl-1 levels (Fig. 5 ). Furthermore, 6 weeks' treatment with either celecoxib or fluvastatin alone only slightly decreased the levels of the apoptosis-related 
Discussion
To explain the potential antitumour effects of celecoxib alone and in combination with fluvastatin, three basic theories may be considered. First and most simply, celecoxib may directly inhibit the proliferation of tumour cells, which is associated with suppression of cyclin, induction of the cell cycle inhibitors p21 Waf1/Cip1 and p27 Kip1 and down-regulation of cyclin-dependent kinase activity. 34, 35 Statins have also been shown to arrest cells in the G 1 phase of the cell cycle by stabilization p21 Waf1/Cip1 and p27 Kip1 . 36, 37 Furthermore, blockade of farnesyl biosynthesis by statins leads to inhibition of the Ras-mediated regulation of proliferation in human tumour cells. 38, 39 In the present study, a combination of celecoxib and fluvastatin produced significantly greater inhibition of cell proliferation compared with either drug alone, while treatment with either celecoxib or fluvastatin alone only had a moderate antiproliferative effect on HCC xenografts in vivo.
Secondly, the observed antitumour effect of celecoxib alone and in combination with fluvastatin may be mediated by agentinduced apoptosis. Celecoxib has been shown to be involved in activation of both the tumour necrosis factor-related apoptosisinducing ligand (TRAIL)-receptor-mediated apoptosis pathway and the mitochondriamediated apoptosis pathway in HCC cells. 40 It has been suggested that a decrease in membrane potential and the dosedependent activation of caspases 8 and 3 are involved in statin-induced apoptosis of HCC cells. 27 In the present study, the combination of celecoxib and fluvastatin resulted in a greater increase in tumour cell apoptosis than that caused by either agent alone, while celecoxib or fluvastatin alone only moderately induced apoptosis. Further studies will be necessary to determine the mechanisms that positively regulate statininduced apoptosis.
Thirdly, HCC is highly malignant and characterized by hypervascularity, and previous studies have demonstrated that inhibition of angiogenesis may be an effective approach in its treatment. 41, 42 Meanwhile, it has been pointed out in previous papers that statins exert biphasic and dose-dependent effects on angiogenesis in vivo and in vitro; low-dose statin treatment induces a pro-angiogenic effect through activation of the Akt/endothelial nitric oxide synthase (eNOS) signalling pathway, whereas high-dose statin treatment may indirectly inhibit angiogenesis. 43, 44 In the present study, fluvastatin was shown to have potent antiangiogenic activities that inhibited tumour growth. These results are consistent with a recently published study showing that treatment with lovastatin was associated with the suppression of angiogenesis in a C3H/He mouse model of HCC. 45 The findings were, however, in contrast to other evidence that suggested that fluvastatin administered alone had no effect on MVD, a measure of angiogenesis. 33 This discrepancy may be due, at least in part, to differences in the experimental systems. In the present study, it was also observed that celecoxib had an antiangiogenic effect in established tumours. Moreover, combined treatment with celecoxib and fluvastatin had a greater inhibitory effect on angiogenesis than with either treatment alone. Taken together, these results suggest J Gao, W-D Jia, J-S Li et al. In vivo anticancer effects of celecoxib and fluvastatin combination therapy that the antitumour effect of celecoxib plus fluvastatin might be mediated in part through their antiangiogenic effects.
The Akt/protein kinase B (PKB) signalling pathway has been shown to play a role in carcinogenesis or progression in various types of cancer, including HCC. 46 Activation of the Akt/PKB signalling pathway has been associated with a variety of biological activities, such as increased cell proliferation, angiogenesis and suppression of apoptosis. 47 It has been shown previously that Akt is commonly activated in many human tumours, including HCC, 48 -50 and that phosphorylation of Akt at Ser 473 is associated with poor prognosis in cancers of the liver. 51, 52 Akt is, therefore, an attractive target for the chemoprevention and treatment of HCC. Inhibition of Akt has been shown to be involved in the potent antitumour effects of celecoxib. 53 As it has been reported that statins induce Akt activation in endothelial cells but not in vascular smooth muscle cells or human tumour cell lines, 54 whether statins can induce Akt activation may be dependent on the cell type examined. Statins have also been shown to inhibit phosphorylation of Akt in a mammalian target of rapamycin (mTOR)-dependent manner in HCC cells. 55 A recent report also showed that statins inhibited the expression of p-Akt in combination with cytotoxic drugs, and sensitized pancreatic cancer cells to cytotoxic drug-induced apoptosis and inhibition of cell proliferation in vitro. 56 Thus, it was hypothesized that combining celecoxib with fluvastatin would result in decreased activation of the Akt pathway. In the present study, the combination of celecoxib and fluvastatin had a greater inhibitory effect on the expression of p-Akt than either treatment alone. These results are in agreement with previous studies 57, 58 and suggest that Akt inhibition may contribute to the antitumour effect of celecoxib alone or celecoxib plus fluvastatin.
The ability of celecoxib to up-regulate the cell cycle inhibitor, p21, has been confirmed in vivo in a human HCC tumour xenograft model. 19 Most recently, statins have also been shown to increase p21 through the inhibition of histone deacetylase activity and the accumulation of acetylated histone-H3. 59 In the present study, the combination of celecoxib with fluvastatin, which produced the greatest in vivo antitumour activity, was shown to be associated with increased levels of p21.
The Mcl-1 protein is a member of the B-cell lymphoma 2 (Bcl-2) family, which plays an important role in cell survival. Mcl-1 is overexpressed in a high percentage of human HCC tumours, 60 and down-regulation of Mcl-1 protein has been shown to induce apoptosis in a HCC cell line, 61 suggesting that Mcl-1 may be a highly attractive molecular target in the treatment of HCC. 62 Celecoxib treatment has been shown to reduce Mcl-1 protein resulting in significant dose-and time-dependent antitumour activity in HCC cells characterized by increased apoptosis and decreased cell proliferation. 40 Meanwhile, previous studies have demonstrated that statins reduce Mcl-1 protein. 63, 64 Thus, it might be speculated that the apoptosis induced by celecoxib or celecoxib plus fluvastatin may be attributed, in part, to a reduction in levels of the antiapoptotic protein, Mcl-1. The combination of celecoxib with fluvastatin produced the greatest effect on apoptosis in the present study and this was shown to be associated with reduced expression of Mcl-1. Further detailed studies are warranted to investigate the molecular mechanisms involved in the synergistic regulation of apoptosis by celecoxib and fluvastatin. In vivo anticancer effects of celecoxib and fluvastatin combination therapy Survivin is a member of the inhibitor of apoptosis protein family, which can directly bind to and potently inhibit the terminal effector cell-death proteases, caspase 3 and caspase 7. 65 Abnormal levels of survivin are involved in the carcinogenesis of various types of cancers. 66 There is a growing body of evidence suggesting that survivin might be a potential target for cancer therapy due to its differential expression in tumour cells compared with that in most normal cells. 67 -70 The ability of celecoxib to induce apoptosis by inhibiting the expression of survivin may be responsible for the chemopreventative effects of this drug. 71 Statins have also been shown to activate a mitochondria-operated apoptosis pathway in breast tumour cells by a mechanism involving both the inhibition of survivin activity and the reduction of survivin protein expression. 72 Treatment with either celecoxib or fluvastatin alone slightly decreased survivin protein expression in tumour tissues in the present study, whereas combined treatment with the two agents demonstrated a more marked reduction.
The regulation of COX-2 protein and its potential role in carcinogenesis in HCC were not evaluated in the present study. A growing body of literature suggests involvement of both COX-2-dependent and -independent mechanisms in celecoxibmediated antineoplastic effects. 73, 74 Further studies are currently underway to determine the role of COX-2-mediated pathways in HCC tumourigenesis and whether COX-2 inhibition is necessary for celecoxib to suppress tumour cell proliferation in vitro or in vivo. Despite these limitations, we suggest that celecoxib, or other relatively selective COX-2 inhibitors, may play a role in the treatment of HCC. It is debatable whether the interaction between celecoxib and fluvastatin is synergistic or additive, although synergistic antitumour activity has recently been reported for celecoxib in combination with statins in vitro. 58 Swamy et al. 29 reported that combined treatment with celecoxib and statins significantly decreased the rate of formation of intestinal polyps in C57BL/6J-APC min/+ mice compared with the use of the single agents alone. Yang et al. 75 recently showed that the triple combination of atorvastatin, γ-tocotrienol and celecoxib significantly inhibited cancer cell growth at a relatively low concentration of each agent. Irrespective of the mechanism of action, the enhanced therapeutic efficacy and benefits of combining celecoxib with statins is without question. These findings, when taken together, highlight another possible explanation which cannot be ruled out for the enhanced antitumour effects of celecoxib and fluvastatin observed in the present study, namely the partial contribution of a drug-drug interaction that results in enhancement of the in vivo antitumour efficacy of celecoxib by fluvastatin.
In summary, the present study provides evidence that the combination of celecoxib and statins induces potent antitumour effects in vivo against HCC xenografts. Administration of celecoxib or fluvastatin alone inhibited tumour growth, but administration of a combination of these drugs was considerably more effective. Further clinical trials should be carried out to define the role of celecoxib, both as a single agent and also in combination with statins for the chemoprevention and treatment of HCC.
